Corvus Pharmaceuticals Inc buy melinda
Start price
26.04.18
/
50%
€8.85
Target price
26.04.18
€9.92
Performance (%)
0.00%
End price
26.04.18
€8.85
Summary
This prediction ended on 26.04.18 with a price of €8.85. The BUY prediction by melinda closed unchanged from the start price. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -4.871% | -4.871% | -0.284% | 822.936% |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by melinda for this prediction
In the thread Corvus Pharmaceuticals Inc diskutieren
SektorBiotechnologische und medizinische Forschung
Corvus Pharmaceuticals gibt den Start der klinischen Phase 1 / 1b-Studie des experimentellen Anti-CD73-Antikörpers CPI-006 bei Patienten mit fortgeschrittenem Krebs bekannt
In einer dreiarmigen Studie wird CPI-006 als Monotherapie in Kombination mit dem Adenosinantagonisten CPI-444 und in Kombination mit Pembrolizumab untersucht
Stopped prediction by melinda for Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€8.88
26.04.18
26.04.18
€9.92
21.05.18
21.05.18
13.06%
21.05.18
21.05.18
Corvus Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€8.02
04.03.18
04.03.18
€10.10
12.03.18
12.03.18
10.91%
12.03.18
12.03.18